Le Lézard
Classified in: Health, Science and technology, Covid-19 virus
Subjects: PARTNERSHIPS, Clinical Study

Lucira and Loch Lomond Villa Announce Clinical Study to Tackle Tripledemic With First and Only Combination COVID-19 and Flu OTC Molecular Self-Test


EMERYVILLE, Calif., Dec. 06, 2022 (GLOBE NEWSWIRE) -- Lucira Health, Inc. (Nasdaq: LHDX) ("Lucira Health" or "Lucira"), a medical technology company, and Loch Lomond Villa, one of New Brunswick's largest long-term health facility operators announced today a clinical study to simultaneously test residents, medical and support staff, and visitors for COVID-19 and Influenza A/B infection with the Lucira COVID-19 & Flu Test.

This pilot will significantly enhance testing and tracking capabilities at Loch Lomond Villa, while allowing medical staff to conduct a comparative and observational study that will help assess the effectiveness of Lucira's testing platform in managing and minimizing COVID-19 and Influenza A/B outbreaks in long-term care settings. Lucira's COVID-19 & Flu Test, the first and only 99% accurate molecular self-test, can provide immediate testing and accurate PCR (polymerase chain reaction) test results for all three viruses.

"Effective testing is the first line of defense in managing respiratory outbreaks," said Loch Lomond Villa Chief Executive Officer, Ms. Cindy Donovan. "The ability of Lucira's platform to simultaneously test for influenza A/B and COVID-19 has the potential to make a huge difference to our residents and staff. We look forward to analyzing and reporting the results."

"Lucira's test means that Canadians no longer need to trade-off speed for accuracy when testing for infection," said Erik Engelson, President and Chief Executive Officer of Lucira Health. "This is the only portable molecular self-test for COVID-19 and the flu on the market, providing lab-quality test results, at home and work, in hospitals or while travelling."

The Lucira COVID-19 & Flu Test is also available for direct purchase by Canadians on Lucira's website: lucirahealth.ca.

About Lucira COVID-19 & Flu Test

The Lucira COVID-19 & Flu Test is a NAAT test utilizing the same platform and device design as Lucira's COVID-19 Test to provide independent diagnoses for COVID-19, Flu A, and Flu B. The single-use test fits in the palm of your hand, runs on two AA batteries, and with one nasal swab, provides a positive or negative result for COVID-19, Flu A, and Flu B in 30 minutes or less. Each Lucira test is packaged with everything needed to run a single test: the test device, two AA batteries, sample vial, swab, and simple instructions. There is no separate reader or instrument to purchase and maintain.

About Lucira Health

Lucira is a medical technology company focused on the development and commercialization of innovative infectious disease tests to make lab-quality diagnostics more accessible. Lucira designed its test platform to provide accurate, reliable, PCR-quality test results anywhere and at any time. Beyond its already commercialized COVID-19 and COVID-19 & Flu Tests, Lucira is working on new diagnostic tests for respiratory infections and other categories including women's health and sexually transmitted infections (STIs). For more information, visit www.lucirahealth.com.

About Loch Lomond Villa

Loch Lomond Villa officially opened its doors in 1973, thanks to the vision and support of East Saint Johns Simonds Lions Club, who foresaw the need for a complete life-care centre for the Saint John area senior population. Loch Lomond Villa's person-centered approach means providing individualized care for all residents and applying the highest standards of care to everything we do. We are focused on the elements of care and support that matter most to residents and their families. In October of 2019, Loch Lomond Villa was awarded Gold Certification for Excellence in Person-Centered Care by Planetree International. This Person-Centered Care Certification recognizes Loch Lomond Villa's achievement and innovation in the delivery of person-centered care. Loch Lomond Villa is one of only 90 healthcare organizations worldwide to receive the Person-Centered Care Gold Certification since the program's launch in 2007. Loch Lomond Villa is also accredited through Accreditation Canada with exemplary status.

Media:

English Canada Media: Holly Windler [email protected]? +1 619-929-1275

Québec & Francophone Media: Martin Croteau [email protected] ? 418-956-6898

Investor Relations:

Greg Chodaczek [email protected] ? 347-620-7010

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/5881b5b9-52d8-4c9a-a0f2-32b880928555



These press releases may also interest you

at 14:45
Lowell Farms Inc. , a California-born cannabis company with advanced production capabilities including extraction, manufacturing, and distribution, will report its financial and operational results for the first fiscal quarter (ended March 31, 2024)...

at 14:45
Mike Alkis is being recognized by The Inner Circle as a Distinguished Professional in the Business Field and for his work at Bizopolis Consulting Inc. Mr. Alkis is considered an expert in re-aligning and restructuring businesses through his company,...

at 14:00
Linda K. Groah, MSN, RN, CNOR, NEA-BC, FAAN, the CEO and Executive Director of AORN (Association of periOperative Registered Nurses), has announced her plans to retire at the end of this year after a new CEO is selected....

at 14:00
Indigenous tourism helps advance economic reconciliation, while allowing the sharing of Indigenous cultures and histories across Canada. That's why supporting its growth, in close partnership with First Nations, Inuit and Métis communities, is one of...

at 13:00
GBank Financial Holdings Inc. (the "Company") , the parent company for GBank (the "Bank"), is pleased to announce that Scot M. Levine has been appointed Executive Vice President and Chief Risk Officer (CRO) of GBank, effective April 29, 2024.  In his...

at 12:00
Law Offices of Howard G. Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against QuidelOrtho Corporation ("QuidelOrtho" or the "Company") . Class Period: February 18, 2022 ?...



News published on and distributed by: